Toxin-induced hepatic injury

Emergency Medicine Clinics of North America

Volumn 32, Issue 1, 2014, Pages 103-125

  Lopez, Annette M ^a,b   Hendrickson, Robert G ^a,b,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c Oregon Poison Center   (United States)

Author keywords

Acetaminophen; Amanita; Ethanol; Liver injury; Management; Statins; Toxin; Valproic acid

Indexed keywords

ACETYLCYSTEINE; AFLATOXIN; ALCOHOL; ALPHA AMANITIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; DANTROLENE; DICLOFENAC; DIDANOSINE; HALOTHANE; IRON; ISONIAZID; KETOCONAZOLE; METHYLDOPA; MINOCYCLINE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYTOIN; PYRAZINAMIDE; SALICYLIC ACID; TETRACYCLINE; TROGLITAZONE; UNINDEXED DRUG; VALPROIC ACID; XENOBIOTIC AGENT; ZIDOVUDINE;

CHRONIC HEPATITIS; FATTY LIVER; HUMAN; INCIDENCE; INTRAHEPATIC CHOLESTASIS; KUPFFER CELL; LIVER CELL; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER INJURY; LIVER NECROSIS; LIVER STRUCTURE; LIVER TOXICITY; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; STEATOSIS; STELLATE CELL; SWEDEN; TOXIN INDUCED HEPATIC INJURY; UNITED KINGDOM;

EID: 84888085968     PISSN: 07338627     EISSN: 07338627     Source Type: Journal    
DOI: 10.1016/j.emc.2013.09.005     Document Type: Review

References (67)

1. Bjornsson E. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther 2010, 32:3-13.
2. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. NEngl J Med 2006, 354:731-739.
3. Lucena M.I., Garcia-Cortes M., Cueto R., et al. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol 2008, 22:141-158.
4. Gunawan B., Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev 2004, 36:301-312.
5. Estes J.D., Stolpman D., Olyaei A., et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 2003, 138:852-858.
6. Nathwani R.A., Kaplowitz N. Drug hepatotoxicity. Clin Liver Dis 2006, 10:207-217. vii.
7. Fontana R.J. Acute liver failure due to drugs. Semin Liver Dis 2008, 28:175-187.
8. Bronstein A.C., Spyker D.A., Cantilena L.R., et al. 2011 annual report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 29th annual report. Clin Toxicol (Phila) 2012, 50:911-1164.
9. Chang C.Y., Schiano T.D. Review article: drug hepatotoxicity. Aliment Pharmacol Ther 2007, 25:1135-1151.
10. Lozano-Lanagran M., Robles M., Lucena M.I., et al. Hepatotoxicity in 2011-advancing resolutely. Rev Esp Enferm Dig 2011, 103:472-479.
11. Chalasani N., Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010, 138:2246-2259.
12. Ghany M., Hoofnagle J.H. Approach to the Patient with Liver Disease. Harrison's Principles of Internal Medicine 2012, McGraw-Hill, New York, Available at: Accessed October 27, 2013. http://www.accessmedicine.com.liboff.ohsu.edu/content.aspx?aID=9132925, 18th edition. D.L. Longo, A.S. Fauci, D.L. Kasper (Eds.).
13. Kaplowitz N., Aw T.Y., Simon F.R., et al. Drug-induced hepatotoxicity. Ann Intern Med 1986, 104:826-839.
14. Timbrell J.A. Drug hepatotoxicity. Br J Clin Pharmacol 1983, 15:3-14.
15. Lee W.M. Drug-induced hepatotoxicity. NEngl J Med 2003, 349:474-485.
16. Larrey D. Drug-induced liver diseases. JHepatol 2000, 32:77-88.
17. Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol 2011, 8:202-211.
18. Pathikonda M., Munoz S.J. Acute liver failure. Ann Hepatol 2010, 9:7-14.
19. Davern T.J., James L.P., Hinson J.A., et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006, 130:687-694.
20. Larson A.M., Polson J., Fontana R.J., et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005, 42:1364-1372.
21. Keays R., Harrison P.M., Wendon J.A., et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991, 303:1026-1029.
22. Kortsalioudaki C., Taylor R.M., Cheeseman P., et al. Safety and efficacy of N-acetylcysteinein children with non-acetaminophen-induced acute liver failure. Liver Transpl 2008, 14:25-30.
23. Lee W.M., Hynan L.S., Rossaro L., et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009, 137:856-864. 864.e1.
24. Stravitz R.T., Kramer A.H., Davern T., et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med 2007, 35:2498-2508.
25. Nguyen N.T., Vierling J.M. Acute liver failure. Curr Opin Organ Transplant 2011, 16:289-296.
26. Chen W.C., Kassi M., Saeed U., et al. Arare case of amatoxin poisoning in the state of Texas. Case Rep Gastroenterol 2012, 6:350-357.
27. Intravenous milk thistle (Silibinin-Legalon) for hepatic failure induced by amatoxin/amanita mushroom poisoning. National Library of Medicine. Available at: Accessed October 24, 2013. http://www.clinicaltrials.gov/ct2/show/NCT00915681?term=nct00915681%26rank=1.
28. Santi L., Maggioli C., Mastroroberto M., et al. Acute liver failure caused by Amanita phalloides poisoning. Int J Hepatol 2012, 2012:487480.
29. Bernal W., Donaldson N., Wyncoll D., et al. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002, 359:558-563.
30. Dabos K.J., Newsome P.N., Parkinson J.A., et al. Abiochemical prognostic model of outcome in paracetamol-induced acute liver injury. Transplantation 2005, 80:1712-1717.
31. Cholongitas E., Theocharidou E., Vasianopoulou P., et al. Comparison of the sequential organ failure assessment score with the King's College Hospital criteria and the model for end-stage liver disease score for the prognosis of acetaminophen-induced acute liver failure. Liver Transpl 2012, 18:405-412.
32. Llado L., Figueras J., Memba R., et al. Is MELD really the definitive score for liver allocation?. Liver Transpl 2002, 8:795-798.
33. Schmidt L.E., Larsen F.S. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007, 45:789-796.
34. Craig D.G., Reid T.W., Martin K.G., et al. The systemic inflammatory response syndrome and sequential organ failure assessment scores are effective triage markers following paracetamol (acetaminophen) overdose. Aliment Pharmacol Ther 2011, 34:219-228.
35. Mitchell I., Bihari D., Chang R., et al. Earlier identification of patients at risk from acetaminophen-induced acute liver failure. Crit Care Med 1998, 26:279-284.
36. Hassanein T.I., Schade R.R., Hepburn I.S. Acute-on-chronic liver failure: extracorporeal liver assist devices. Curr Opin Crit Care 2011, 17:195-203.
37. Chun L.J., Tong M.J., Busuttil R.W., et al. Acetaminophen hepatotoxicity and acute liver failure. JClin Gastroenterol 2009, 43:342-349.
38. Laleman W., Wilmer A., Evenepoel P., et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006, 10:R108.
39. Schmidt L.E., Wang L.P., Hansen B.A., et al. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003, 9:290-297.
40. Sen S., Davies N.A., Mookerjee R.P., et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004, 10:1109-1119.
41. Sorkine P., Ben Abraham R., Szold O., et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001, 29:1332-1336.
42. Khuroo M.S., Farahat K.L. Molecular adsorbent recirculating system for acute andacute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004, 10:1099-1106.
43. Lee K.H., Lee M.K., Sutedja D.S., et al. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 2005, 25:973-977.
44. Stauber R.E., Krisper P., Zollner G., et al. Extracorporeal albumin dialysis in a patient with primary sclerosing cholangitis: effect on pruritus and bile acid profile. Int J Artif Organs 2004, 27:342-344.
45. Krisper P., Haditsch B., Stauber R., et al. Invivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. JHepatol 2005, 43:451-457.
46. Karvellas C.J., Bagshaw S.M., McDermid R.C., et al. Acase-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. Blood Purif 2009, 28:151-158.
47. Sauer I.M., Goetz M., Steffen I., et al. Invitro comparison of the molecular adsorbent recirculation system (MARS) and single-pass albumin dialysis (SPAD). Hepatology 2004, 39:1408-1414.
48. Detry O., Arkadopoulos N., Ting P., et al. Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure. Am Surg 1999, 65:934-938.
49. Hughes R.D., Williams R. Use of bioartificial and artificial liver support devices. Semin Liver Dis 1996, 16:435-444.
50. Hodgman M.J., Garrard A.R. Areview of acetaminophen poisoning. Crit Care Clin 2012, 28:499-516.
51. Daly F.F., O'Malley G.F., Heard K., et al. Prospective evaluation of repeated supratherapeutic acetaminophen (paracetamol) ingestion. Ann Emerg Med 2004, 44:393-398.
52. Dart R.C., Erdman A.R., Olson K.R., et al. Acetaminophen poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2006, 44:1-18.
53. Lheureux P.E., Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009, 47:101-111.
54. Murray K.F., Hadzic N., Wirth S., et al. Drug-related hepatotoxicity and acute liver failure. JPediatr Gastroenterol Nutr 2008, 47:395-405.
55. Silva M.F., Aires C.C., Luis P.B., et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. JInherit Metab Dis 2008, 31:205-216.
56. Schmid M.M., Freudenmann R.W., Keller F., et al. Non-fatal and fatal liver failure associated with valproic acid. Pharmacopsychiatry 2013, 46:63-68.
57. Thanacoody R.H. Extracorporeal elimination in acute valproic acid poisoning. Clin Toxicol (Phila) 2009, 47:609-616.
58. Cress C.M., Malliah A., Herrine S.K. Image of the month. Fulminant hepatic failure caused by Amanita phalloides toxicity. Clin Gastroenterol Hepatol 2011, 9:A26.
59. Escudie L., Francoz C., Vinel J.P., et al. Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. JHepatol 2007, 46:466-473.
60. Enjalbert F., Rapior S., Nouguier-Soule J., et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. JToxicol Clin Toxicol 2002, 40:715-757.
61. Schwartz J.M., Reinus J.F. Prevalence and natural history of alcoholic liver disease. Clin Liver Dis 2012, 16:659-666.
62. Giboney P.T. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician 2005, 71:1105-1110.
63. Amini M., Runyon B.A. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. World J Gastroenterol 2010, 16:4905-4912.
64. Lewis J.H. Clinical perspective: statins and the liver-harmful or helpful?. Dig Dis Sci 2012, 57:1754-1763.
65. Russo M.W., Scobey M., Bonkovsky H.L. Drug-induced liver injury associated with statins. Semin Liver Dis 2009, 29:412-422.
66. Kleiner D.E. The pathology of drug-induced liver injury. Semin Liver Dis 2009, 29:364-372.
67. Delaney K.A. Hepatic Principles. Goldfrank's Toxicologic Emergencies 2011, McGraw-Hill, New York, Chapter 26, Table 26-4. p. 376. 9th editon. L.S. Nelson, N.A. Lewin, M.A. Howland (Eds.).